Business In Brief
AMAG's Feraheme gets CMS Q-codes: AMAG Pharmaceuticals' novel I.V. anemia therapyFeraheme (ferumoxytol) brought in about $3 million in third-quarter sales, largely due to launch pilots. But non-dialysis chronic kidney disease providers are buying significantly more product than dialysis organizations, execs said during an Oct. 29 earnings call. "This does not mean that our sales will continue to be weighted towards non-dialysis CKD, but it's indicative of the differences in the sales cycle between the two segments," said Timothy Healey, Senior VP-Commercial Operations. Before switching products, dialysis organizations consider how a drug performs, how it will affect work flow and contractual incentives - reimbursement is crucial since that is how the dialysis businesses get paid. In a positive nod, CMS assigned Feraheme two unique temporary Medicare Q-codes for dialysis and pre-dialysis patients just a few months after the drug gained FDA approval in June (1"The Pink Sheet," July 6, 2009). The Q-codes, effective Jan. 1 2010, will speed reimbursement since they are product-specific and don't require a claim-by-claim manual review
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.